A detailed history of Harbor Capital Advisors, Inc. transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 168,506 shares of RCKT stock, worth $2.2 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
168,506
Previous 97,134 73.48%
Holding current value
$2.2 Million
Previous $2.09 Million 48.83%
% of portfolio
0.14%
Previous 0.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$17.6 - $25.88 $1.26 Million - $1.85 Million
71,372 Added 73.48%
168,506 $3.11 Million
Q2 2024

Jul 09, 2024

BUY
$20.66 - $26.72 $324,527 - $419,717
15,708 Added 19.29%
97,134 $2.09 Million
Q1 2024

May 13, 2024

BUY
$26.16 - $30.74 $708,177 - $832,162
27,071 Added 49.8%
81,426 $2.19 Million
Q4 2023

Jan 08, 2024

SELL
$16.78 - $31.94 $49,702 - $94,606
-2,962 Reduced 5.17%
54,355 $1.63 Million
Q3 2023

Oct 20, 2023

BUY
$15.07 - $24.05 $30,667 - $48,941
2,035 Added 3.68%
57,317 $1.17 Million
Q2 2023

Jul 11, 2023

BUY
$16.59 - $23.6 $33,329 - $47,412
2,009 Added 3.77%
55,282 $1.1 Million
Q1 2023

Apr 26, 2023

SELL
$15.79 - $22.6 $185,311 - $265,233
-11,736 Reduced 18.05%
53,273 $912,000
Q4 2022

Jan 20, 2023

SELL
$15.5 - $22.76 $21,715 - $31,886
-1,401 Reduced 2.11%
65,009 $0
Q3 2022

Oct 28, 2022

SELL
$12.37 - $18.41 $90,709 - $135,000
-7,333 Reduced 9.94%
66,410 $1.06 Million
Q2 2022

Jul 26, 2022

SELL
$7.96 - $16.64 $11,414 - $23,861
-1,434 Reduced 1.91%
73,743 $1.02 Million
Q1 2022

Apr 28, 2022

SELL
$13.16 - $23.68 $173,817 - $312,765
-13,208 Reduced 14.94%
75,177 $1.19 Million
Q4 2021

Feb 04, 2022

BUY
$21.52 - $36.02 $1.9 Million - $3.18 Million
88,385 New
88,385 $1.93 Million

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $987M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Harbor Capital Advisors, Inc. Portfolio

Follow Harbor Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.